Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (4671)	7/30/1998 7:01:00 PM
From: Uncle Frank	Read Replies (2) \| Respond to of 9523

*OT* > I still own some LSI (heart-breaking...). My condolences, Anthony. I held LSI for over 2 1/2 years. A wonderful company with leading edge technology, and it cost me 25% of my investment to stick with them. I swore their last ER would be my last LSI disappointment, broke my emotional attachment, and sold at a ridiculous 22 1/2. Those dollars are in csco, and have already started earning me money. Probably a good lesson in investing for me. Frank

To: Anthony Wong who wrote (4671)	7/31/1998 5:55:00 AM
From: flickerful	Read Replies (1) \| Respond to of 9523

featuring Erogenex Corp, a skewed article on a on-Rx female (and male) potency pill, without (so-called viagra "red flags") side effects.......................................................................................... <<Viagra-Type Product Now Available Without Prescription for Both Men and Women >> LOS ANGELES--(BW HealthWire)--July 30, 1998--While Pfizer continues to attempt a female version of Viagra, Erogenex Corp. has broken through with non-prescription formulas for both men and women. The Erogenex formula (Ex22) has 20 years of research and clinical studies, with no documented side effects. The big difference between the product Pfizer is formulating and the Erogenex capsule is the fact that the Erogenex formula (Ex22) requires no prescription. Dr. Patricia O. Britton, Ph.D., a spokesperson for Erogenex, was quick to point out that: "This is not a female potency pill. What it does do is help to stimulate sexual desire and function." Erogenex claims the pill boosts libido, endurance, increases lubrication in women and stamina for an "overall, close-to-perfect experience." The pill also comes in a male formula, which the company claims offers the same results as far as increased libido, endurance and stamina, as well as helping in the ability to achieve and maintain erections. It seems that Viagra's competition is rising almost as quickly as its sales. Along with Erogenex, many others clamor to take advantage of this profitable market. [ÿZonagenÿ] , a Texas-based drug maker, hopes to have its impotence pill, Vasomax, which would take less time to work than Viagra, on the market by the end of the year. [ÿIcos Corp.ÿ] , TAP Holdings and Bio Technology General are all working on rival treatments. Pentech Pharmaceuticals of Wheeling, Ill., has a drug in late-stage testing. Indianapolis-based Eli-Lilly & Co. and New York-based Bristol-Meyers Squibb Co. are looking to make drugs from scratch through partnerships or from drugs now slated for other uses. Along with rising competition are rising concerns, as it is not yet known what results these other drugs will have. Red flags were raised when the FDA posted a synopsis of fatal outcome reports linked to Viagra, the one drug now being marketed. This means that numerous deaths are being linked to taking Viagra, according to Erogenex. The Erogenex formula, Ex22, is available without a prescription and is a fraction of the cost of Viagra. The company says it stands behind its product 100 percent and will offer a full refund to any dissatisfied customer. Weighing the risks and benefits of the competition, Erogenex may have a lot to offer. Erogenex does not claim to treat sexual dysfunction and is not an impotence pill; but it does claim that this is a product that could give Viagra and the rest of the competition a run for their money. For interviews with a spokesperson from Erogenex, contact Red Rock Entertainment & Media at 702/242-6986. For further information on the Erogenex Formula (Ex22) visit the Website at www.erogenex.com. (Copyright 1998)